CANbridge Acquires Rare Liver Disease Drug in $120 Million Agreement
publication date: Apr 30, 2021
CANbridge Pharma of Beijing has acquired Greater China rights to develop maralixibat, a treatment for a set of rare inherited childhood liver diseases caused by impaired bile flow. Mirum Pharma is developing maralixibat, a clinical-stage oral medication, for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia. CANbridge will pay $11 million upfront and be responsible for $109 million in milestones, plus royalties. It will also oversee Mirum’s clinical sites in China to accelerate enrollment of a global Phase IIb maralixibat test for biliary atresia. More details....
Stock Symbol: (NSDQ: MIRM)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.